Carotenoids in the treatment of age-related macular degeneration: a drug delivery system does matter
<p> M.L. Maksimov<sup>1–3</sup>, J.G. Oganezova<sup>3,4</sup>, I.D. Kanner<sup>5</sup>, A.A. Voznesenskaya<sup>6</sup> </p> <p> <sup>1</sup>Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuo...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2023-03-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/42c/jj6lg2g6xyb6pxsb5k1ic4m13jzk115x.pdf |
| Summary: | <p>
M.L. Maksimov<sup>1–3</sup>, J.G. Oganezova<sup>3,4</sup>, I.D. Kanner<sup>5</sup>, A.A. Voznesenskaya<sup>6</sup>
</p>
<p>
<sup>1</sup>Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russian Federation
</p>
<p>
<sup>2</sup>Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
</p>
<p>
<sup>3</sup>Pirogov Russian National Research Medical University, Moscow, Russian Federation
</p>
<p>
<sup>4</sup>Research Center for Medical Genetics, Moscow, Russian Federation
</p>
<p>
<sup>5</sup>Lomonosov Moscow State University, Moscow, Russian Federation
</p>
<p>
<sup>6</sup>National Medical Research Center of Endocrinology, Moscow, Russian Federation
</p>
<p>
<br>
</p>
<p>
Age-related macular degeneration (AMD) is one of the leading causes of low vision and blindness worldwide for people over age 60. By 2040, the number of people living with macular degeneration is expected to reach 288 million due to the exponential acceleration of population aging. A decline in visual functions caused by AMD has a significant economic impact in all countries. Besides aging, there are other multiple heterogenic risk factors associated with AMD: gender, environmental condition, lifestyle, genetic characteristics, chronic inflammatory processes in the human body, level of education, etc. It is important for the ophthalmologist to be aware of modifiable risk factors and thus to collect a comprehensive medical history, interact with patients using motivational interviewing and to involve promptly other healthcare specialists into the patient management strategy. Etiopathogenesis of AMD is still not entirely understood. However, it is known that the major pathways include age-related alterations of retinal pigment epithelium (RPE) cells, oxidative stress, dysregulated lipid metabolism, inflammation, hemodynamic changes, and neovascularization. Carotenoids lutein and zeaxanthin are natural compounds with a proven efficacy in reducing AMD progression, which have been demonstrated to act as medications for patients with early AMD stages. The micro-encapsulated formula offers such an advantage as gradual and controlled release of active substances.
</p>
<p>
<b>Keywords</b>: age-related macular degeneration, risk factors, etiopathogenesis, carotenoids, lutein, zeaxanthin, microcapsules.
</p>
<p>
<b>For citation: </b>Maksimov M.L., Oganezova J.G., Kanner I.D., Voznesenskaya A.A. Carotenoids in the treatment of age-related macular degeneration: a drug delivery system does matter. Russian Journal of Clinical Ophthalmology. 2023;23(1):60–65 (in Russ.). DOI: 10.32364/2311-7729-2023-23-1-60-65.
</p> |
|---|---|
| ISSN: | 2311-7729 2619-1571 |